Geron, Investors Reach $6.25M Settlement In Cancer Drug Suit
By Martin O'Sullivan ( March 3, 2017, 2:42 PM EST) -- A proposed class of Geron Corp. investors have sought approval in California federal court for a $6.25 million settlement regarding claims that the company improperly touted a cancer drug before the U.S. Food and Drug Administration halted a clinical trial over liver toxicity concerns....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.